Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters

被引:7
作者
Gupta, Sarika [1 ]
Karandikar, Nitin J. [1 ]
Ginader, Timothy [2 ]
Bellizzi, Andrew M. [1 ]
Holman, Carol J. [1 ]
机构
[1] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA
[2] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
关键词
plasma cell myeloma; monoclonal gammopathy; immunophenotyping; flow cytometry; MINIMAL RESIDUAL DISEASE; MONOCLONAL GAMMOPATHY; MULTIPLE-MYELOMA; BONE-MARROW; UNDETERMINED SIGNIFICANCE; RISK-FACTOR; PROGRESSION; EXPRESSION; CRITERIA; DIAGNOSIS;
D O I
10.1002/cyto.b.21624
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BackgroundMultiparametric flow cytometry is a useful tool for diagnosis of plasma cell (PC) dyscrasias and assessment of minimal residual disease in plasma cell myeloma (PCM). However, the immunophenotypic differences between the clonal PCs of PCM and those of monoclonal gammopathy of undetermined significance (MGUS) as well as the correlation of these flow cytometric markers with pertinent laboratory parameters have not been evaluated. MethodsWe retrospectively identified all newly diagnosed treatment-naive PCM and MGUS patients between 09/2014 and 06/2015 who underwent 10-color flow-cytometric evaluation: CD45, CD38, CD138, cKappa, cLambda, CD19, CD27, CD28, CD56, CD117. FACSDiva analysis was used to identify antigenic aberrancies and associations with pertinent laboratory parameters were evaluated. ResultsAll cases demonstrated at least two aberrancies. There was a trend toward a greater number of aberrancies in PCM, with 68% showing >/= 4 aberrancies compared with 44% in MGUS (P=0.11). The only marker more frequently aberrant in one disease class was CD19, aberrant in 68% of PCM and 25% of MGUS (P<0.01). In PCM, significant associations were found for CD56 non-aberrancy (P=0.05) and the presence of amyloid and CD27 aberrancy and normal serum albumin (P=0.05). In MGUS, CD117 expression was associated with normal hemoglobin (P=0.03). ConclusionsThe PCs of PCM show a trend toward more antigenic aberrancy than those of MGUS. There is significant association between the antigenic profiles of PCM/MGUS and clinical parameters including amyloidosis, albumin level, and hemoglobin. (c) 2018 International Clinical Cytometry Society
引用
收藏
页码:500 / 508
页数:9
相关论文
共 38 条
  • [1] CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis
    Bataille, Regis
    Pellat-Deceunynck, Catherine
    Robillard, Nelly
    Avet-Loiseau, Herve
    Harousseau, Jean-Luc
    Moreau, Philippe
    [J]. LEUKEMIA RESEARCH, 2008, 32 (03) : 379 - 382
  • [2] Human cytomegalovirus infection of tumor cells downregulates NCAM (CD56): A novel mechanism for virus-induced tumor invasiveness
    Blaheta, RA
    Beecken, WD
    Engl, T
    Jonas, D
    Oppermann, E
    Hundemer, M
    Doerr, HW
    Scholz, M
    Cinatl, J
    [J]. NEOPLASIA, 2004, 6 (04): : 323 - 331
  • [3] Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro
    Blaheta, RA
    Hundemer, M
    Mayer, G
    Vogel, JU
    Kornhuber, B
    Cinatl, J
    Markus, BH
    Driever, PH
    Cinatl, J
    [J]. CELL COMMUNICATION AND ADHESION, 2002, 9 (03) : 131 - 147
  • [4] Multiparameter Immunophenotyping by Flow Cytometry in Multiple Myeloma: The Diagnostic Utility of Defining Ranges of Normal Antigenic Expression in Comparison to Histology
    Cannizzo, Elisa
    Bellio, Emanuele
    Sohani, Aliyah R.
    Hasserjian, Robert P.
    Ferry, Judith A.
    Dorn, Michelle E.
    Sadowski, Craig
    Bucci, Janessa J.
    Carulli, Giovanni
    Preffer, Frederic
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2010, 78B (04) : 231 - 238
  • [5] Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma
    Cesana, C
    Klersy, C
    Barbarano, L
    Nosari, AM
    Crugnola, M
    Pungolino, E
    Gargantini, L
    Granata, S
    Valentini, M
    Morra, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1625 - 1634
  • [6] DRACH J, 1991, CLIN EXP IMMUNOL, V83, P418
  • [7] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [8] Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma
    Flores-Montero, Juan
    de Tute, Ruth
    Paiva, Bruno
    Juan Perez, Jose
    Boettcher, Sebastian
    Wind, Henk
    Sanoja, Luzalba
    Puig, Noemi
    Lecrevisse, Quentin
    Belen Vidriales, Maria
    van Dongen, Jacques J. M.
    Orfao, Alberto
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2016, 90 (01) : 61 - 72
  • [9] HARADA H, 1993, BLOOD, V81, P2658
  • [10] Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
    Katzmann, J. A.
    Clark, R.
    Kyle, R. A.
    Larson, D. R.
    Therneau, T. M.
    Melton, L. J., III
    Benson, J. T.
    Colby, C. L.
    Dispenzieri, A.
    Landgren, O.
    Kumar, S.
    Bradwell, A. R.
    Cerhan, J. R.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2013, 27 (01) : 208 - 212